Company / Cash & Equivalents
GeneDx Holdings Corp. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$105.0M
FY2025
5-year range
$85.2M / $400.6M
FY2021-FY2025
Trend
+23.2%
vs FY2024
Sector context
#110 of 152
Health Care
What the data says
At $105M, GeneDx Holdings Corp.'s cash & equivalents ranks #110 of 152 in the Health Care sector. Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $105M.
Based on SEC 10-K filings.
$105M in FY2025 with a 5-year CAGR of -0.6%.
Improved from $100M to $105M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -5.4%
- 5-Year CAGR
- -0.6%
- 10-Year CAGR
- -
Sector benchmark
#110 of 152 in Health CareTop 72% of 152This company $105.0M Sector average $1.2B
▼
-91.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -0.6%, indicating a declining trend.
- In FY2025, cash & equivalents increased 23.2% year-over-year.
- Ranks #110 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- Negative profit margin: -17.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $105.0M | +23.2% |
| FY2024 | $85.2M | -14.5% |
| FY2023 | $99.7M | -19.6% |
| FY2022 | $123.9M | -69.1% |
| FY2021 | $400.6M | +270.4% |
| FY2020 | $108.1M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026